Take orally once daily in the evening, with or without food. For asthma, take in the evening. For allergic rhinitis, timing may be individualized. Continue taking it regularly even if you feel well.

Montelukast selectively antagonizes the cysteinyl leukotriene 1 (CysLT1) receptor. Cysteinyl leukotrienes are potent inflammatory eicosanoids released from various cells, including mast cells and eosinophils, and cause bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment, all of which contribute to asthma and allergic rhinitis symptoms. By blocking these receptors, Montelukast reduces these inflammatory effects.

• •Hypersensitivity to montelukast or any excipients of the product
• •Not indicated for the reversal of bronchospasm in acute asthma attacks

Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.

In cases of overdose, the most frequently reported adverse experiences were thirst, somnolence, mydriasis, hyperkinesia, and abdominal pain. Treatment is symptomatic and supportive. No specific antidote is known.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. It is unknown if montelukast is excreted in human milk; use with caution during lactation.